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Background & Aims: A subset of patients with functional dyspepsia (FD) present with early 
satiation and weight loss, for which there are no established therapeutic options. We 
investigated the efficacy of mirtazapine (an anti-depressant and antagonist of the histamine 
receptor H1, the α2 adrenergic receptor, and the serotonin receptors 5-HT2C and 5-HT-3) in 
patients with FD and weight loss.  
 
Methods: We conducted a randomized, placebo-controlled pilot trial studied 34 patients with 
FD (29 women; mean age, 35.9±2.3 years) with weight loss >10% of original body weight 
(mean loss of 12.4±2.3 kg) without depression or anxiety. After a run-in period, patients were 
randomly assigned to groups given placebo (n=17) or mirtazapine 15 mg each day for 8 
weeks (n=17), in a double-blind manner. Subjects were evaluated during a 2-week baseline 
and 8-week treatment for dyspepsia symptom severity, quality of life (based on the Nepean 
Dyspepsia Index), and gastrointestinal-specific anxiety; they were given a nutrient challenge 
test and weighed. Data were analyzed using linear mixed models followed by planned 
contrasts with adaptive stepdown Bonferroni multiple testing correction.  
 
Results: Two patients in each group dropped out. At weeks 4 and 8, mirtazapine significantly 
reduced mean dyspepsia symptom severity scores compared to week 0 (P=.003 and P=.017, 
respectively); there was no significant reducing in the placebo group (P>.37 for weeks 4 and 
8). The difference in change from week 0 between mirtazapine and placebo showed a trend 
with a large effect size at week 4 (P=.059) that was not significant at week 8 (P=.55). 
However, improvements from week 0 to weeks 4 and 8 were significantly larger in the 
mirtazapine than placebo group for early satiation, quality of life, gastrointestinal-specific 
anxiety, weight, and nutrient tolerance (mostly with large effect sizes).  
 
Conclusions: In a randomized, placebo-controlled trial, mirtazapine significantly improved 
early satiation, quality of life, gastrointestinal-specific anxiety, nutrient tolerance, and weight 
loss in patients with FD. Clinicaltrial.gov number, NCT01240096. 
 
KEY WORDS: stomach, gastric barostat, gastric accommodation, gastric emptying, clinical 
trial, drug 
 
 
INTRODUCTION 
 
Functional dyspepsia (FD), defined as the presence of symptoms thought to 
originate in the gastroduodenal region in the absence of any organic, systemic or 
metabolic disease that is likely to explain the symptoms, is one of the most common 
gastrointestinal disorders(1). According to Rome III criteria, early satiation, 
postprandial fullness, epigastric pain and epigastric burning constitute the typical FD 
symptoms. Other symptoms like upper abdominal bloating, belching and nausea 
often co-exist, and a subset of patients may experience weight loss(1,2). 
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Weight loss is normally considered an alarm symptom(1), but may be present in up to 
13% of subjects with dyspeptic symptoms in the general population and up to 40% of 
tertiary care FD patients(3-6). Weight loss in dyspepsia is associated with symptoms 
of early satiation and epigastric pain, both in the general population and in tertiary 
care(3-6). Impairment of gastric accommodation, a relaxation of the proximal 
stomach that provides the meal with a reservoir enabling a gastric volume increase 
without a rise in pressure(7), may underlie weight loss in FD (3). Impaired 
accommodation occurs in 40% of FD patients, and these have more prevalent 
symptoms of early satiation and weight loss (4). Based on observations in healthy 
controls and FD patients, restoration of accommodation is a valid therapeutic target 
to improve early satiation and weight recovery(4,7,8). 
 
At present, there is no efficacious treatment for FD patients with weight loss. 
Mirtazapine is an antidepressant with H1-, α2-, 5-HT2c- and 5-HT3-receptor 
antagonistic properties. Its use in depression is associated with weight gain. In part 
through its 5-HT3-receptor antagonistic action, mirtazapine has nausea-suppressive 
properties, and anecdotal observations suggest efficacy for mirtazapine in FD, but 
controlled studies are lacking(9,10). 
 
Our aim was to conduct a randomized, double-blind placebo-controlled mechanistic 
pilot trial to evaluate the influence of mirtazapine on symptoms, gastric emptying 
rate, and nutrient tolerance in FD patients with weight loss.  
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MATERIALS AND METHODS 
 
Patient selection 
 
Patients (aged 20-70 years) with FD according to the Rome III criteria and with 
weight loss in excess of 10% of their body weight since onset of symptoms were 
eligible(1). Organic or metabolic disease was excluded by routine biochemistry, 
upper abdominal ultrasound and upper gastrointestinal endoscopy. During 
endoscopy, biopsies were taken from antrum and corpus and stained for the 
presence of Helicobacter pylori. Dyspeptic symptoms had to be present at least 3 
days per week, with 2 or more symptoms scored as relevant or severe on the 
symptom questionnaire (see below).  
 
Exclusion criteria were the presence of esophagitis, gastric atrophy or erosive 
gastroduodenal lesions on endoscopy, heartburn as predominant symptom, a history 
of peptic ulcer or major abdominal surgery. All drugs potentially affecting 
gastrointestinal motility or sensitivity (acid-suppressives, prokinetics, drugs affecting 
gastric acid secretion and analgesics other than paracetamol) were discontinued at 
least one week prior to the start of the study and were forbidden for the entire course 
of the study. 
 
Patients with current anxiety or depression based on the HADS questionnaire (see 
below), with anorexia nervosa or other eating disorders, and patients on 
antipsychotics or antidepressants during the last 6 weeks were not eligible. Pregnant 
women or patients of childbearing potential without effective contraception were also 
excluded.  
 
Informed consent was obtained from each participant and the protocol had been 
approved by the University Hospital Ethics Committee prior to the start of the study. 
The study was registered on www.clinicaltrials.gov as NCT01240096. 
 
 
Study design 
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The study design is summarized in Supplementary Figure 1. Patients underwent a 
gastric barostat study (details in Supplement) prior to a two-week run-in period. At the 
end of the run-in period and after the treatment period, patients underwent a octanoic 
acid breath test to quantify solid gastric emptying, a nutrient drink challenge test to 
quantify nutrient volume tolerance(17-19) (details in Supplement) and filled out a 
dyspepsia symptom severity (DSS) questionnaire previously shown to be 
reproducible and sensitive to change(12,13) and consisting of 8 dyspeptic symptoms 
(epigastric pain, postprandial fullness, upper abdominal bloating, early satiation, 
nausea, vomiting, epigastric burning, belching) during the last two weeks on a Likert 
scale (absent, mild, moderate, severe). DSS is defined as the sum of all 8 items. In 
addition, they filled out the Hospital Anxiety Depression Scale (HADS), the Visceral 
Sensitivity Index (VSI) and the short-form Nepean Dyspepsia Index (SF-NDI)(14-16). 
The HADS allows to quantify anxiety and depression severity, through 7 questions 
per subscale(14). The VSI is a 15-item questionnaire for assessment of 
gastrointestinal-specific anxiety(15). The NDI is a 25-item questionnaire assessing 5 
subscales of quality of life impact in FD: tension/sleep, interference, eating/drinking, 
knowledge/control, and work/study (16). After the 2-week run-in period, patients were 
randomly assigned to 8 weeks with mirtazapine 15 mg or a matching placebo melting 
tablet, taken at bedtime. The 15 mg dose was chosen based on tolerability, clinical 
experience, literature reports, and on the traditional use of lower doses of 
psychotropic drugs for FGID(1,9,10). Both active drug and matching placebo were 
supplied by the manufacturer (MSD Belgium, Brussels, Belgium). The questionnaires 
were filled out again after 4 weeks of the treatment period. To provide details on 
onset of changes in symptom intensities during treatment, patients also filled out a 
daily diary indicating severity for the same dyspeptic symptoms on 100mm visual 
analogue scales. 
 
  
Statistical analysis 
 
All authors had access to the study data and reviewed and approved the final 
manuscript. Descriptive data are given as mean±SD. All outcomes were analyzed 
using linear mixed models; estimates are given as mean±SEM. Effect sizes are given 
as Cohen’s d. A 2x3 mixed ANOVA model was used with “drug” (mirtazapine, 
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placebo) as between-subject factor and “week” (0, 4, 8) as within-subject factor. The 
drug-by-week interaction effect was the effect of primary interest which was followed 
up by the following planned contrasts, with stepdown Bonferroni multiple testing 
correction. First, the outcomes were compared between week 0, week 4 and week 8 
within each treatment arm separately by paired Student’s t-tests. Second, for each 
outcome, the change between week 0 on the one hand and week 4 and week 8 on 
the other hand were compared between treatment arms using independent sample 
Student’s t-tests.  
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RESULTS 
 
Patient characteristics 
 
Thirty-four patients (29 women, mean age 35.9±13.5, BMI 22.1±3.9 kg/m2) were 
enrolled. They reported FD symptoms since 14(4-222) months and had a mean 
weight loss of 12.4±9.7 kg since the onset of symptoms. An acute symptom onset, 
suggestive of post-infectious FD, was reported by 65%. According to Rome III 
criteria, 17 had postprandial distress syndrome (PDS), 9 epigastric pain syndrome 
(EPS) and 8 both EPS and PDS. 
 
Table 1 summarizes the symptom pattern at the end of the run-in period. All patients 
were Helicobacter pylori negative and none had a previous history of eradication; 
15% had delayed gastric emptying for solids (t1/2 range 111-134 min), one patient had 
rapid emptying (t1/2 27 mins), 50% had impaired gastric accommodation and 44% 
were hypersensitive to gastric balloon distention. At baseline, anxiety and depression 
levels, as assessed by the HADS questionnaire, were 6.4±4.6 and 5.0±3.6 
respectively. Seventeen FD patients were randomized to active drug and 17 to 
placebo. These groups did not differ in demographics, symptom pattern and anxiety 
and depression rates at randomisation (Table 2). 
 
 
Conduct of the study and adverse events 
 
No serious adverse events occurred. During the double-blind phase, a total of 4 
patients dropped out: two in the placebo arm because of lack of therapeutic effect 
and 2 in the mirtazapine arm because of adverse events of fatigue and sleepiness.  
 
 
Dyspepsia symptom severity 
 
The drug-by-week interaction showed a trend [F(2,59)=2.63, p=0.08]. Planned 
contrasts revealed a significant difference between week 0 (10.9±0.9) and week 4 
(7.9±1.3) as well as week 8 (8.6±1.4) for mirtazapine (p=0.003 and p=0.017, 
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respectively). For placebo, there were no significant differences between week 0 
(11.4±0.9) and week 4 (11.1±1.2) or week 8 (10.4±1.0) (p=0.38 and p=0.72, 
respectively). The difference in change from week 0 between mirtazapine and 
placebo showed a trend at week 4 (-3.0±0.9 versus -0.3±0.8, p=0.059, d=0.82) but 
not at week 8 (-2.6±0.9 versus -1.0±0.8, p=0.55, d=0.48) (Figure 1A). Results of per 
protocol analysis are given in Supplement.  
 
For early satiation, where the drug-by-week interaction was significant [F(2,59)=6.96, 
p=0.002]. Planned contrasts revealed a significant difference between week 0 
(1.88±0.21) and week 4 (1.06±0.25) as well as week 8 (1.11±0.24) for mirtazapine 
(p=0.002 and p=0.0003, respectively). For placebo, there were no significant 
differences between week 0 (1.53±0.19) and week 4 (1.47±0.17) or week 8 
(1.77±0.22) (p=0.71 and p=0.56, respectively). The difference in change from week 0 
between mirtazapine and placebo was significant at week 4 (-0.82±0.24 versus -
0.06±0.16, p=0.019, d=0.96) and at week 8 (-0.77±0.19 versus -0.24±0.22, p=0.002, 
d=0.67) (Figure 1B). No significant effects were found for the other three cardinal FD 
symptoms. For nausea, the drug-by-week interaction effect was not significant 
[F(2,32)=2.03, p=0.15], but planned contrasts revealed a trend for the difference 
between week 0 (1.53±0.24) and week 4 (1.02±0.25) as well as week 8 (1.09±0.26) 
for mirtazapine (p=0.074 and p=0.096, respectively). The supplementary file provides 
information on symptom evaluation with daily diaries.    
 
 
Weight 
 
The drug-by-week interaction was significant [F(2,58)=12.82, p<0.0001]. Planned 
contrasts revealed that during placebo treatment, no significant change in body 
weight occurred compared to week 0 (59.0±2.7) at either week 4 (59.1±2.7, p=1.0) or 
week 8 (58.8±2.6, p=1.0). Mirtazapine treatment, on the contrary, was associated 
with significant weight gain compared to week 0 (67.0±3.5) at both week 4 (69.5±3.5, 
p=0.0008) and week 8 (70.9±3.7, p<0.0001). The difference in weight change from 
week 0 between mirtazapine and placebo was significant at week 4 (2.5±0.6 versus 
0.1±0.3, p=0.003, d=1.40) and week 8 (3.9±0.7 versus -0.2±0.4, p<0.0001, d=1.86) 
(Figure 2A). In terms of percentage of original body weight, the differences were -
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0.2±2.2 and 6.4±4.6% respectively (p<0.0001). 
 
 
Nutrient tolerance 
 
At baseline, nutrient tolerance was below the lower normal range of 979 kcal in 91% 
of the patients (16). The drug-by-week interaction was significant [F(1,26)=8.24, 
p=0.008]. Planned contrasts showed that after placebo treatment, no significant 
change in nutrient tolerance occurred at week 8 (638.3±77.7 kcal) compared to week 
0 (668.4±75.0 kcal) (p=0.44). After mirtazapine treatment, nutrient tolerance was 
significantly improved at week 8 (704.2±67.5 kcal) compared to week 0 (542.7±42.3 
kcal) (p=0.007). The change between week 8 and week 0 was significantly different 
between mirtazapine and placebo (+161.5±54.9 kcal versus -30.1±37.9 kcal, 
p=0.008, d=1.05) (Figure 2B). The change in nutrient volume tolerance was not 
correlated to baseline weight or BMI, or to the weight loss prior to therapy and the 
weight gain during therapy.  
 
 
Gastric emptying 
 
The drug-by-week interaction was not significant [F(1,30)=2.46, p=0.13]. In planned 
contrasts, no significant differences were found either within treatment arms [week 0 
versus week 8: 79.1±7.0 versus 85.8±8.6 (p=0.15) for placebo; 88.5±7.0 versus 
77.0±7.8 (p=0.45) for mirtazapine] or for the difference week 8 - week 0 between 
mirtazapine and placebo (-11.5±7.7 versus +6.7±8.6 minutes, p=0.13, d=0.57). 
 
 
Questionnaires 
 
Quality of life (SF-NDI) 
A significant drug-by-week interaction effect was found [F(2,32)=4.61, p=0.018]. In 
the mirtazapine arm, scores decreased significantly from week 0 (31.7±2.1) to week 
4 (25.1±2.5, p=0.001) and week 8 (24.6±2.7, p=0.001). In the placebo arm, no 
significant changes were found from week 0 (30.9±2.1) to week 4 (29.5±2.5, p=0.83) 
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nor to week 8 (30.8±2.7, p=0.95). The change from week 0 was significantly different 
between mirtazapine (-7.1±1.8) and placebo (0.1±1.8) at week 8 (p=0.033, d=1.03), 
with a trend with large effect size (p=0.092, d=0.84) at week 4 (-6.6±1.6 and 1.4±1.6 
for mirtazapine and placebo, respectively). The results for the 5 NDI subscales are 
summarized in Table 3. Significant drug-by-week interaction effects as well as 
significant between-treatment differences for the change from week 0 to week 8 were 
found for eating/drinking and work/study. 
 
Anxiety and depression (HADS) 
Anxiety and depression scores were not significantly altered by 8 weeks of placebo 
treatment, but mirtazapine treatment was associated with a small but statistically 
significant improvement of anxiety at week 8 compared to week 0 (Table 3). No 
significant between-treatment differences were found. Changes in depression or 
anxiety scores were not correlated to changes in symptom scores and did not predict 
treatment responses.  
 
Gastrointestinal-specific anxiety (VSI) 
A significant drug-by-week interaction effect was found [F(2,31)=6.7, p=0.004]. This 
was driven by the fact that mirtazapine significantly improved VSI ratings, with no 
significant change under placebo treatment, resulting in a significant difference for 
the change from baseline at week 4 (-11.5±3.2 versus +1.3±2.3, p=0.003, d=1.19) 
which was maintained at week 8 (-11.3±4.1 versus +0.4±2.9, p=0.03, d=0.85) (Table 
3). Changes in VSI were not correlated to symptom improvement or weight recovery. 
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DISCUSSION 
 
FD is a highly prevalent condition, with no established efficacious therapy. Current 
approaches focus on acid suppressive or prokinetic drugs, but symptomatic benefit is 
insufficient in many patients(1,2,24,25). In the subgroup of FD patients with 
unintentional weight loss, the lack of efficacious treatment options is even more 
troubling. In this pilot study in FD with weight loss, mirtazapine 15 mg in the evening 
improved early satiation scores and nutrient tolerance compared to placebo. A trend 
(with large effect size) was found for overall dyspepsia symptom score at week 4, but 
not week 8. This was associated with significant recovery of weight loss and 
improvement of quality of life and visceral specific anxiety scores. 
The symptomatic benefit of mirtazapine was most consistent across questionnaire 
and diaries for the symptom of early satiation (DSS, diaries), and to a lesser extent 
for nausea (diaries, trend in DSS). Symptoms of epigastric pain and burning were not 
affected, suggesting that mirtazapine treatment may be most beneficial for the PDS 
subgroup(1), although the study was not powered for subgroup analysis. Based on 
the diaries, symptomatic benefit seems to occur from week 3 onwards. Early satiation 
responds best to mirtazapine, suggesting that the drug specifically affects the 
mechanism underlying this symptom (accommodation and its signalling to the brain). 
Nausea only significantly improved after mirtazapine in the diary assessment, where 
improvement, albeit to a lesser extent, also occurred with placebo, without significant 
differences between both arms. This probably reflects the limited sample size of this 
mechanistic pilot trial, and the possibility that the 100 mm VAS is more sensitive to 
small changes than the 4-level DSS severity scale. 
Based on its pharmacological profile, mirtazapine may improve FD symptoms 
through a number of mechanisms. The drug is used for treating depression and 
anxiety. Anxiety or depression co-morbidity in FD is high(26), and in healthy 
volunteers, experimentally induced anxiety is associated with impaired 
accommodation to a meal and decreased nutrient tolerance(27). In hypersensitive FD 
patients, state anxiety is significantly correlated with lower discomfort and pain 
thresholds, and decreased compliance during gastric balloon distention(28). 
However, patients in the present study were selected for absence of anxiety and 
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depression co-morbidity and symptom improvement was not correlated to changes in 
anxiety and depression. Mirtazapine treatment was associated with significant 
improvement of gastrointestinal-specific anxiety(29). In a previous study, we found a 
significant negative correlation between VSI scores and impairment of duodenal 
mucosal integrity in FD(30). It is unclear whether improvement in gastrointestinal-
specific anxiety with mirtazapine occurs secondarily to improvement of FD symptoms 
and weight recovery, or whether mirtazapine directly affects its putative central 
mechanisms. The lack of correlation with symptom improvement would argue against 
the former mechanism. Based on this finding, it is conceivable that the drug might be 
effective in other functional disorders with high gastrointestinal-specific anxiety such 
as IBS.  
The symptoms that most consistently improved during mirtazapine treatment are 
early satiation and weight loss. In several pathophysiological and mechanistic 
studies, impaired gastric accommodation has been associated with early satiation 
and weight loss(2,4,7,8,19,31). The prevalence of impaired accommodation in the 
current patient group was 50% at baseline, but the protocol did not include a repeat 
gastric barostat assessment during treatment. Previously, we proposed the satiety 
drinking test as a surrogate marker for gastric accommodation(19). Using this test, 
nutrient volume tolerance was significantly increased by mirtazapine, but not placebo. 
These findings argue in favor of enhanced gastric accommodation by mirtazapine. 
However, a central mechanism involving increased appetite through 5-HT2C receptor 
antagonism can also be involved(32). Hence, further specific mechanistic studies are 
needed to confirm whether or not mirtazapine enhances gastric accommodation in 
man. If the effect of mirtazapine on nutrient tolerance and body weight does not 
involve enhanced accommodation, but rather reflects a central effect, the drug may 
also be effective in the treatment of other functional disorders with weight loss, where 
impaired accommodation is not the underlying mechanism. 
The present study has a number of limitations. Due to the setting and nature of this 
pilot trial, we enrolled only tertiary care patients and the sample size is limited. 
Hence, findings are not necessarily applicable to non-tertiary care FD. Furthermore, 
due to the small sample size, baseline measurements were not always similar, 
although no significant differences between both groups were found. However, the 
latter issue was handled by using linear mixed models and planned contrasts to 
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compare the change from baseline between treatment arms. Finally, the sample size 
precludes separate analysis in PDS and EPS patients. 
To date, enhanced accommodation in FD has been observed with tegaserod, 
buspirone and acotiamide(33-36), but whether these drugs allow recovery of weight 
loss in FD has not been addressed (19,35,39). Mirtazapine was acceptably well 
tolerated in the present study, but two out of seventeen patients discontinued the 
drug for drowsiness, a well-known adverse event with mirtazapine use(40). Hence, 
the present pilot study shows that mirtazapine has the potential to become the 
treatment of choice for FD patients with weight loss, and evaluation in larger multi-
center studies is warranted. 
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TABLES 
 
Table 1. Symptom profile in the patient population at the end of the run-in 
period (n=34).  
Rows indicate the number of patients for each symptom severity level. 
 
Symptom Absent Mild Moderate Severe 
Postprandial fullness 0 8 22 4 
Upper abdominal bloating 0 8 21 5 
Early satiation 4 6 20 4 
Epigastric pain 4 11 14 5 
Nausea 6 9 14 5 
Belching 10 12 9 3 
Epigastric burning 14 12 6 2 
Vomiting 24 6 1 3 
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Table 2. Characteristics of the patients in both groups. 
 
Variable Placebo 
group 
Mirtazapine 
group 
p 
Age (years) 39.9±3.5 31.8±2.7 NS 
Sex (f/m) 15/2 14/3 NS 
BMI (kg/m2) 20.8±1.0 24.1±1.2 NS 
Weight loss (kg) 11.1±2.5 14.4±4.5 NS 
DSS 11.4±0.9 10.9±0.9 NS 
Minimal distending 
pressure (MDP) (mm 
Hg) 
6.7±0.3 7.5±0.3 NS 
Fasting discomfort 
threshold (mm Hg 
above MDP) 
9.3±1.1 8.3±0.9 NS 
Gastric compliance 
(ml/mm Hg) 
74±8 62±15 NS 
Gastric 
accommodation (ml) 
80±36 64±29 NS 
HAD anxiety 7.5±1.3 5.2±0.7 NS 
HAD depression 4.8±0.7 5.1±1.2 NS 
VSI 29.4±4.9 33.7±3.5 NS 
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Table 3. Influence of 8 weeks of treatment with placebo or mirtazapine on SF-
NDI subscales, HADS and VSI.  
*p<0.05, ***p<0.001 compared to week 0 within the mirtazapine treatment arm. Bold 
indicates significant drug-by-week interaction effect and significant between-group 
difference for the change from week 0 to week 8. 
 
(sub)scale baseline 
mirtazapine 
8 weeks 
mirtazapine 
baseline 
placebo 
8 weeks 
placebo 
Short-form Nepean Dyspepsia Index 
Tension 4.8±0.6 4.0±0.6 6.1±0.6 5.7±0.6 
Interference with 
daily activities 
6.9±0.7 5.0±0.8* 6.3±0.7 5.9±0.8 
Eating/drinking 8.0±0.5 5.8±0.6*** 7.6±0.5 7.3±0.6 
Knowledge/control 3.9±0.3 3.4±0.3 4.8±0.5 4.2±0.5 
Work/study 8.1±0.8 6.4±1.0* 6.1±0.8 7.6±1.0 
Hospital Anxiety and Depression Scale 
Anxiety 5.2±0.7 3.9±0.8* 7.5±1.3 4.1±0.8 
Depression 5.1±1.2 3.9±1.2 4.8±0.7 4.9±1.1 
Visceral Sensitivity Index 
VSI 33.7±4.2 22.8±4.2*** 31.2±4.3 31.6±4.3 
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FIGURES 
 
Figure 1.  
A. Change in Dyspepsia Symptom Severity Score after 8 weeks of mirtazapine 
or placebo.  
B. Individual line plots of changes in severity ratings of early satiety.  
*p<0.05, **p<0.01, ***p<0.001 compared to baseline within the mirtazapine arm. 
†p<0.05,  ††p<0.01 change from baseline between treatments. 
 
Figure 2.  
A. Change in body weight after 4 and 8 weeks of treatment with placebo or 
mirtazapine.  
B. Change in meal volume tolerance during a nutrient challenge test after 8 
weeks treatment with placebo or mirtazapine treatment.  
**p<0.01, ***p<0.001 compared to baseline within the mirtazapine arm. ††p<0.01, 
†††p<0.001 change from baseline between treatments. 
 
Supplementary Figure 1. Schematic study outline. 
 
Supplementary Figure 2. Influence of 8 weeks placebo treatment on daily diary 
ratings of dyspeptic symptoms.  
A. Early satiation 
B. Postprandial fullness  
C. Epigastric pain 
D. Nausea 
*p<0.05, **p<0.01 compared to baseline within the mirtazapine arm. #p<0.05,  
##p<0.01 compared to baseline within the placebo arm.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
CONSORT 2010 Flow Diagram 
Assessed for eligibility (n=34) 
Excluded  (n=  0 ) 
♦   Not meeting inclusion criteria (n= 0 ) 
♦   Declined to participate (n= 0 ) 
♦   Other reasons (n= 0 ) 
Analysed  (n= 17 ) 
♦ Excluded from analysis (give reasons) (n=  ) 
Lost to follow-up (give reasons) (n= 0 ) 
Discontinued intervention (lack of therapeutic 
effect) (n= 2 ) 
Allocated to placebo (n= 17 ) 
♦ Received allocated intervention (n= 17 ) 
♦ Did not receive allocated intervention (give 
reasons) (n= 0 ) 
Lost to follow-up (give reasons) (n= 0 ) 
Discontinued intervention (side effects) (n= 2 ) 
Allocated to mirtazapine (n= 17 ) 
♦ Received allocated intervention (n= 17 ) 
♦ Did not receive allocated intervention (give 
reasons) (n= 0 ) 
Analysed  (n= 17 ) 
♦ Excluded from analysis (give reasons) (n=  ) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=  34) 
Enrollment 
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METHODS 
 
Gastric emptying breath test 
 
Gastric emptying rates for solids and liquids were determined using the 14C-octanoic 
acid and 13C-glycin breath test respectively (17,18). In the treatment phases of the 
study, study medication was ingested 15 minutes prior to the meal. The test meal 
consisted of 60 g of white bread, an egg, the yolk of which was doped with 74 kBq of 
14C-octanoic acid sodium salt (DuPont, NEN Research, Boston, MA, USA) and 300 
ml of water in which 100 mg 13C-glycin (99% enrichment; Isotec, Miamisburg, OH, 
USA) was dissolved. All meals were consumed within a 5 minute period. The total 
caloric value of the test meal was 250 kcal. Breath samples were taken before the 
meal and at 15-minute intervals for a period of 240 minutes postprandially. At each 
sampling point, the subject exhaled into two different containers for measuring 
exhaled 13C and 14C respectively. The radiation in the container containing the 14C 
sample was determined by liquid scintillation counting while the 13C breath content 
was determined by on-line gas chromatographic purification-isotope ratio mass 
spectrometry as described before (17,18).   
 
 
Satiety drink test 
 
 A peristaltic pump (Minipuls2, Gilson, Villiers-Le-Bel,France) dispensed a liquid meal 
(Nutridrink, Nutricia, Belgium) in one of two beakers at a rate of 15ml/min. Patients 
were requested to maintain intake of the liquid meal at a rate equal to the dispensing 
rate, thereby alternating the beakers as they are filled and emptied. At 5-minute 
intervals, they scored their satiety and other epigastric sensations using a graphic 
rating scale that combines verbal descriptors on a scale graded from 0 to 5 
(1=threshold, 5=maximum satiety). Patients were instructed to cease the meal intake 
when a score of 5 was reached (4,19). 
 
 
Gastric barostat study 
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Following an overnight fast of at least 12 hours, a double lumen polyvinyl tube (Salem 
sump tube 14 Ch., Sherwood Medical, Petit Rechain, Belgium) with an adherent 
plastic bag (1200 ml capacity; 17 cm maximal diameter) finely folded, was introduced 
through the mouth and secured to the subject's chin with adhesive tape. The position 
of the bag in the gastric fundus was checked fluoroscopically. The polyvinyl tube was 
then connected to a programmable barostat device (Synectics Visceral Stimulator, 
Stockholm, Sweden). To unfold the bag, it was inflated with a fixed-volume of 300 ml 
of air for two minutes with the study subject in a recumbent position, and again 
deflated completely. The subjects were then positioned in a comfortable sitting 
position with the knees bent (80°) and the trunk up right in a specifically designed bed.  
 
After a 30 minute adaptation period, minimal distending pressure (MDP) was first 
determined by increasing intrabag pressure by 1 mm Hg every 3 minutes until a 
volume of 30 ml or more was reached. Subsequently, isobaric distentions were 
performed in stepwise increments of 2 mm Hg starting from MDP, each lasting for 2 
minutes, while the corresponding intragastric volume was recorded. Subjects were 
instructed to score their perception of upper abdominal sensations at the end of every 
distending step, using a graphic rating scale that combined verbal descriptors on a 
scale graded 0-6 (4,5). The endpoint of each sequence of distentions was established 
at an intrabag volume of 1000 ml, or when the subjects reported discomfort or pain 
(score 5 or 6). After a 30 minute adaptation period with the bag completely deflated, 
the pressure level was set at MDP+2 mm Hg during at least 90 minutes. In the 
treatment phases of the study, study medication was ingested after 15 minutes (i.e. 
15 minutes prior to the meal). After 30 minutes, a liquid meal (200 ml, 300 kcal, 13% 
proteins, 48% carbohydrates, 39%, Nutridrink®, Nutricia, Bornem, Belgium) was 
administered. In all patients gastric tone measurement was continued for 60 minutes 
after the meal.  
 
Data analysis 
 
Gastric half emptying time (t1/2) were calculated from the 13CO2 and 14CO2 excretion 
curves as previously described (17,18).  
 
The endpoint of the satiety test was the amount of calories ingested until the 
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occurrence of maximum satiety (score 5) (4,19).  
 
In the gastric barostat studies, for each 2 minute distending period, the intragastric 
volume was calculated by averaging the recording. Perception threshold was defined 
as the first level of pressure and the corresponding volume that evoked a perception 
score of 1 or more. Discomfort threshold was defined as the first level of pressure 
and the corresponding volume that provoked a score of 5 or more. Hypersensitivity to 
gastric distention was defined as a discomfort threshold below the mean minus 2 
standard deviations in healthy volunteers (<6.6 mm Hg) (4,5). Gastric tone before 
and after administration of the meal was measured by calculation of the mean 
balloon volume for consecutive 5 minute intervals. The meal-induced gastric 
relaxation was quantified as the difference between the average volumes during 30 
minutes before and 60 minutes after the administration of the meal. Impaired 
accommodation to a meal was defined as a meal-induced relaxation below the mean 
minus 2 standard deviations in healthy volunteers (<64 ml) (4,5). 
 
Statistical analysis 
 
The primary outcome variable was the improvement in DSS scores from baseline. 
Secondary outcome variables were the effects of treatment on the severity of the 4 
individual cardinal dyspepsia symptoms and nausea in the DSS, on solid gastric 
emptying, on weight and nutrient tolerance and on quality of life scores. The study 
was powered with 85% sensitivity at p<0.05. The sample size was calculated based 
on a previous study(20), and the 30% was based on existing regulatory views and 
recommendations for clinically meaningful benefit in functional disorders(21,22). 
 
 
RESULTS 
 
Dyspepsia symptom severity and weight evolution 
 
Per protocol analysis 
In PP analysis, the drug-by-week interaction effect was borderline significant 
[F(2,55)=3.11, p=0.053]. Planned contrasts revealed a significant difference between 
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week 0 (10.2±0.7) and week 4 (6.8±1.0) as well as week 8 (7.5±1.1) for mirtazapine 
(p=0.001 and p=0.004, respectively). For placebo, there were no significant 
differences between week 0 (11.6±1.1) and week 4 (11.2±1.4) or week 8 (10.5±1.0) 
(p=0.67 and p=0.38, respectively). The difference in change from week 0 between 
mirtazapine and placebo was significant at week 4 (-3.4±0.9 versus -0.4±0.9, 
p=0.049, Cohen’s d=0.86) but not at week 8 (-2.7±0.8 versus -1.1±0.8, p=0.31, 
Cohen’s d=0.52).  
 
 
Daily diaries 
 
The weekly average scores for the 3 cardinal FD symptoms available in the diaries (epigastric 
pain, postprandial fullness, early satiation) as well as nausea are summarized in Figure 3. 
Compared to the run-in period, placebo treatment was associated with significant improve-
ment in nausea ratings at week 2 and week 8. With mirtazapine, compared to the run-in pe-
riod, significant improvement occurred for severity ratings of early satiation from week 3 
onwards, nausea improved from week 2 until week 5 included, and postprandial fullness 
improved at week 4 only. No significant improvement in pain ratings was found in any of the 
treatment arms. For early satiation, the drug-by-week interaction effect was borderline sig-
nificant [F(8,226)=1.96, p=0.052], indicating a different evolution of early satiation ratings 
between the two treatment arms (Supplementary Figure 2). 
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